论文部分内容阅读
目的探讨吡格列酮对糖尿病患者的临床疗效和对肾脏的保护作用。方法选取早期糖尿病肾病患者50例,在原控制血糖方案基础上加用罗格列酮30 mg/d,观察3个月,治疗前后分别检测患者空腹血糖(FBG)、糖化血红蛋白(HbA1c)、收缩压(SBP)、舒张压(DBP)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、尿微量白蛋白排泄率(UAER)、C-反应蛋白(CRP)、c肽。结果患者FBG、HbA1c、SBP、DBP、TG、UAER、CRP、c肽下降及HDL-C上升,具有统计学意义。结论吡格列酮治疗糖尿病肾病效果显著,在降糖的同时亦可减少尿蛋白排泄,有一定的肾脏保护作用。
Objective To investigate the clinical efficacy and the protective effect of pioglitazone on diabetic patients. Methods Fifty patients with early diabetic nephropathy were enrolled in this study. Rosiglitazone 30 mg / d was given on the basis of the original control glucose regimen for 3 months. The levels of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), systolic blood pressure SBP, DBP, TG, HDL-C, UAER, CRP and c-peptide were determined. Results The decrease of FBG, HbA1c, SBP, DBP, TG, UAER, CRP and c-peptide and the increase of HDL-C were statistically significant. Conclusion Pioglitazone is effective in treating diabetic nephropathy. It can also decrease urinary protein excretion and have certain protective effects on kidneys.